{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:26:53Z","timestamp":1786955213012,"version":"build-2736575974"},"reference-count":94,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Oral small-molecule inhibitors of activated factor XI (FXIa) are intended to attenuate thrombosis with less disruption of hemostasis than established anticoagulants, but clinical outcomes have not consistently paralleled pharmacodynamic target engagement. This systematic review integrated molecular design, preclinical pharmacology, human pharmacokinetics\/pharmacodynamics (PK\/PD), and clinical outcomes to identify where translation is maintained or lost. Methods: The review followed PRISMA 2020 and PRISMA-S and was registered in PROSPERO (CRD420261356169). PubMed\/MEDLINE, Scopus, and Web of Science Core Collection were searched from inception through 30 March 2026 and rerun on 11 August 2026, with a final publication-eligibility cut-off of 30 June 2026. Owing to heterogeneity, evidence was synthesized narratively. Results: Sixty-eight eligible reports were included, comprising seven randomized parent outcome trials and nine reports with in vivo thrombosis or bleeding experiments. In the OCEANIC-STROKE trial, ischemic stroke occurred in 6.2% with asundexian versus 8.4% with placebo (HR 0.74, 95% CI 0.65\u20130.84), while major bleeding was 1.9% versus 1.7% (HR 1.10, 95% CI 0.85\u20131.44). In OCEANIC-AF, stroke or systemic embolism occurred in 1.3% with asundexian versus 0.4% with apixaban (HR 3.79, 95% CI 2.46\u20135.83), despite less major bleeding (0.2% vs. 0.7%; HR 0.32, 95% CI 0.18\u20130.55). Conclusions: Oral small-molecule FXIa inhibition is pharmacologically coherent, but clinical benefit is indication-, comparator-, and background-therapy-dependent. PD markers confirm target engagement but are not validated efficacy surrogates; hard clinical outcomes remain decisive.<\/jats:p>","DOI":"10.3390\/ph19081298","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:05:41Z","timestamp":1786953941000},"page":"1298","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational Development of Oral FXIa Inhibitors: A Systematic Review of Molecular Design, Pharmacology, and Indication-Specific Clinical Evidence"],"prefix":"10.3390","volume":"19","author":[{"given":"Micha\u0142","family":"Janiak","sequence":"first","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Jurasza 2 Str., 85-089 Bydgoszcz, Poland"},{"name":"Doctoral School of Medical and Health Sciences, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University in Toru\u0144, Jagiello\u0144ska 13-15 Str., 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-0290","authenticated-orcid":false,"given":"Katarzyna","family":"M\u0105dra-Gackowska","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Faculty of Health Sciences, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Sk\u0142odowskiej Curie 9 Str., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0408-9623","authenticated-orcid":false,"given":"Lidia","family":"Wydeheft","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Faculty of Health Sciences, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Sk\u0142odowskiej Curie 9 Str., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-7108","authenticated-orcid":false,"given":"Marcin","family":"Gackowski","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Jurasza 2 Str., 85-089 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-2001-14668","article-title":"Epidemiology of venous thromboembolism","volume":"1","author":"Kearon","year":"2001","journal-title":"Semin. Vasc. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e24052","DOI":"10.1016\/j.heliyon.2024.e24052","article-title":"Global burden of atrial fibrillation\/flutter: Trends from 1990 to 2019 and projections until 2044","volume":"10","author":"Ma","year":"2024","journal-title":"Heliyon"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/ehjcvp\/pvae016","article-title":"Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation","volume":"10","author":"Binding","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102350","DOI":"10.1016\/j.rpth.2024.102350","article-title":"Oral anticoagulation for stroke prevention in atrial fibrillation and advanced kidney disease","volume":"8","author":"Ballegaard","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1358863X231206778","article-title":"Factor XI\/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review","volume":"29","author":"Prakash","year":"2024","journal-title":"Vasc. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1055\/a-2061-3311","article-title":"Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis","volume":"7","author":"Wang","year":"2023","journal-title":"TH Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bcp.13520","article-title":"First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects","volume":"84","author":"Perera","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study","volume":"87","author":"Beale","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, R., Guan, X., Hu, P., Dong, Y., Zhu, Y., Zhang, T., Zou, J., and Zhang, S. (2022). First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.821363"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13787","DOI":"10.1111\/cts.13787","article-title":"Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose-escalation phase I study","volume":"17","author":"Zhang","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jth.15744","article-title":"First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men","volume":"20","author":"Nowotny","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102932","DOI":"10.1016\/j.rpth.2025.102932","article-title":"The factor XIa antibody osocimab strongly inhibits clotting in extracorporeal circuits with human blood and in baboons","volume":"9","author":"Samaha","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: A novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jacbts.2024.12.005","article-title":"Inhibition of Factor XI Using RBD4059: A Novel GalNAc-siRNA With Potent and Durable Antithrombotic Effects","volume":"10","author":"Liang","year":"2025","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1111\/jth.14606","article-title":"A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding","volume":"17","author":"Abdelfadiel","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1021\/jm5002698","article-title":"Allosteric inhibition of human factor XIa: Discovery of monosulfated benzofurans as a class of promising inhibitors","volume":"57","author":"Argade","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ma, T., Dong, Y., Huang, L., Yang, Y., Geng, Y., Fei, F., Xie, P., Zhao, Y., Lin, H., and Yang, Z. (2022). SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1027627"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40261-023-01281-8","article-title":"The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers","volume":"43","author":"Xu","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the Prevention of Venous Thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): An international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): A phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus Apixaban in Patients with Atrial Fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"OCEANIC-STROKE Investigators. Asundexian for Secondary Stroke Prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10760296251335967","DOI":"10.1177\/10760296251335967","article-title":"A Systematic Review of Factor XI\/XIa Inhibitors Versus Direct Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"31","author":"Xue","year":"2025","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ekir.2024.10.007","article-title":"A Systematic Review of Safety and Efficacy of Factor XI\/XIa Inhibitors in Patients with ESKD on Hemodialysis","volume":"10","author":"Steiner","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: An extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e13895","DOI":"10.1111\/cts.13895","article-title":"Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data","volume":"17","author":"Chen","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13318-023-00838-4","article-title":"Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans","volume":"48","author":"Piel","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/bcp.15981","article-title":"Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: Target in vitro and in vivo studies","volume":"90","author":"Kanefendt","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s40262-024-01435-7","article-title":"Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian","volume":"63","author":"Brase","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/cpdd.1207","article-title":"Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian","volume":"12","author":"Kanefendt","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cpdd.1366","article-title":"No Influence of Asundexian on Cardiac Repolarization","volume":"13","author":"Brase","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e70142","DOI":"10.1002\/psp4.70142","article-title":"Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic\/Cardiovascular Events","volume":"15","author":"Yassen","year":"2026","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): A multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamacardio.2025.0277","article-title":"Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial","volume":"10","author":"Alexander","year":"2025","journal-title":"JAMA Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacc.2023.12.004","article-title":"Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials","volume":"83","author":"Eikelboom","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/STROKEAHA.123.043198","article-title":"Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes","volume":"55","author":"Smith","year":"2024","journal-title":"Stroke"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/17474930231216339","article-title":"Cerebral microbleeds and asundexian in non-cardioembolic ischemic stroke: Secondary analyses of PACIFIC-STROKE","volume":"19","author":"Balali","year":"2024","journal-title":"Int. J. Stroke"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/STROKEAHA.123.045204","article-title":"Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE","volume":"55","author":"Chen","year":"2024","journal-title":"Stroke"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Leader, J.H., Koolaji, S., Hossain, M.M., Mutch, N.J., and Gorog, D.A. (2026). Asundexian and apixaban exert differential effects on thrombin generation: Insights from OCEANIC-AF. Eur. Heart J., ehag337.","DOI":"10.1093\/eurheartj\/ehag337"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16591","DOI":"10.1038\/s41598-024-67182-8","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and\/or clopidogrel in healthy participants","volume":"14","author":"Perera","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-022-08768-y","article-title":"Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants","volume":"12","author":"Perera","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/DDDT.S488414","article-title":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults","volume":"19","author":"Luo","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e70058","DOI":"10.1111\/cts.70058","article-title":"Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approach","volume":"17","author":"Jarugula","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"22239","DOI":"10.1038\/s41598-022-25936-2","article-title":"Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor","volume":"12","author":"Perera","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40119-022-00266-6","article-title":"Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor","volume":"11","author":"Perera","year":"2022","journal-title":"Cardiol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40262-022-01110-9","article-title":"Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants","volume":"61","author":"Perera","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40262-022-01150-1","article-title":"Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment","volume":"61","author":"Perera","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cpt.70037","article-title":"Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation","volume":"119","author":"Zhou","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e70015","DOI":"10.1002\/cpdd.70015","article-title":"A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants","volume":"15","author":"Zannikos","year":"2026","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jtha.2025.06.028","article-title":"Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation","volume":"23","author":"Yin","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"109564","DOI":"10.1016\/j.thromres.2025.109564","article-title":"The in vitro anticoagulant effect of milvexian in healthy neonates and children","volume":"257","author":"Letunica","year":"2026","journal-title":"Thromb. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1021\/acs.jmedchem.1c02153","article-title":"Targeting the S2 Subsite Enables the Structure-Based Discovery of Novel Highly Selective Factor XIa Inhibitors","volume":"65","author":"Yao","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10419","DOI":"10.1021\/acs.jmedchem.2c00442","article-title":"Discovery of Potent and Orally Bioavailable Pyridine N-Oxide-Based Factor XIa Inhibitors through Exploiting Nonclassical Interactions","volume":"65","author":"Xu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1021\/acs.jmedchem.0c00464","article-title":"Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"117436","DOI":"10.1016\/j.ejmech.2025.117436","article-title":"Discovery of potent, highly selective, and orally bioavailable factor XIa inhibitors for anticoagulant therapy","volume":"289","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"118457","DOI":"10.1016\/j.ejmech.2025.118457","article-title":"Design, synthesis and biological evaluation of novel FXIa inhibitors featuring five-membered heterocycles as P2\u2032 fragments","volume":"303","author":"Wu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1007\/s11030-024-11024-2","article-title":"Structure-based design and synthesis of novel FXIa inhibitors targeting the S2\u2032 subsite for enhanced antithrombotic efficacy","volume":"29","author":"Wu","year":"2025","journal-title":"Mol. Divers."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Fjellstr\u00f6m, O., Akkaya, S., Beisel, H.-G., Eriksson, P.-O., Erixon, K., Gustafsson, D., Jurva, U., Kang, D., Karis, D., and Knecht, W. (2015). Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0113705"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wei, Q., Zheng, Z., Zhang, S., Zheng, X., Meng, F., Yuan, J., Xu, Y., and Huang, C. (2018). Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors. Molecules, 23.","DOI":"10.3390\/molecules23082002"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1039\/D4MD01013B","article-title":"Design, synthesis, and biological evaluation of substituted oxopyridine derivatives as selective FXIa inhibitors","volume":"16","author":"Wang","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"117067","DOI":"10.1016\/j.ejmech.2024.117067","article-title":"Discovery of potent and selective factor XIa inhibitors incorporating triazole-based benzoic acid as novel P2\u2019 fragments: Molecular dynamics simulations and anticoagulant activity","volume":"282","author":"Dai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"113437","DOI":"10.1016\/j.ejmech.2021.113437","article-title":"Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment","volume":"220","author":"Lei","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kaya, A.O., Emre, M.C., and Emre, N. (2026). Machine Learning-Driven QSAR Modeling of FXIa Inhibitors for Virtual Screening and Rational Drug Design. Pharmaceuticals, 19.","DOI":"10.3390\/ph19060912"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Novichikhina, N., Ilin, I., Tashchilova, A., Sulimov, A., Kutov, D., Ledenyova, I., Krysin, M., Shikhaliev, K., Gantseva, A., and Gantseva, E. (2020). Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo [3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa. Molecules, 25.","DOI":"10.3390\/molecules25081889"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Novichikhina, N.P., Shestakov, A.S., Medvedeva, S.M., Lagutina, A.M., Krysin, M.Y., Podoplelova, N.A., Panteleev, M.A., Ilin, I.S., Sulimov, A.V., and Tashchilova, A.S. (2023). New Hybrid Tetrahydropyrrolo [3,2,1-ij]quinolin-1-ylidene-2-thioxothiazolidin-4-ones as New Inhibitors of Factor Xa and Factor XIa: Design, Synthesis, and In Silico and Experimental Evaluation. Molecules, 28.","DOI":"10.3390\/molecules28093851"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Skoptsova, A.A., Geronikaki, A., Petrou, A., Novichikhina, N.P., Podoplelova, N.A., Bykov, G.A., Anis\u2019kov, A.A., Soloveva, S.A., and Shikhaliev, K.S. (2025). Design, Synthesis, and In Vitro and In Silico Study of New Hybrid 1-(2-(4-Arylthiazol-2-yl)hydrazineylidene)-5,6-dihydro-4H-pyrrolo [3,2,1-ij]quinolin-2-ones as Factor Xa and Factor XIa Inhibitors. Molecules, 30.","DOI":"10.3390\/molecules30173544"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"115762","DOI":"10.1016\/j.bmc.2020.115762","article-title":"Studies on fragment-based design of allosteric inhibitors of human factor XIa","volume":"28","author":"Boothello","year":"2020","journal-title":"Bioorg Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/cbdd.14053","article-title":"Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies","volume":"100","author":"Parsaeian","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Buckley, G.T., Crowley, M.P., and Harte, J.V. (2024). Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays. Diagnostics, 14.","DOI":"10.3390\/diagnostics14171991"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jtha.2025.05.030","article-title":"Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents","volume":"23","author":"Buckley","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"102950","DOI":"10.1016\/j.rpth.2025.102950","article-title":"Impact of asundexian on a panel of coagulation assays","volume":"9","author":"Vassart","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Goubeau, L., Curis, E., Delavenne, X., Gouin-Thibault, I., Hodin, S., Genin, A., Demagny, J., Menard, F., Faille, D., and Mouton, C. (2026). A comprehensive multicenter study assessing the impact of abelacimab, asundexian and milvexian on coagulation assays. Blood Adv.","DOI":"10.1182\/bloodadvances.2026020472"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"102600","DOI":"10.1016\/j.rpth.2024.102600","article-title":"The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in vitro","volume":"8","author":"Bunce","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.jtha.2025.05.032","article-title":"DOAC-Stop reverses the anticoagulant effect of asundexian and milvexian","volume":"23","author":"Fitzpatrick","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.jtha.2025.06.016","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: An in vitro study","volume":"23","author":"Hardy","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012\u20132021","volume":"166","author":"Stevens","year":"2024","journal-title":"Chest"},{"key":"ref_94","unstructured":"Dishy, V., Sha, S., Koshkina, A., Tesfaye, F., Plotnikov, A.N., Makimura, H., and Chintala, M. (2026). Reversal of the Anticoagulant Effect of Milvexian by 4-Factor Prothrombin Complex Concentrate and Recombinant Factor VIIa in Healthy Participants: A Two-Part, Randomized, Crossover Study. J. Cardiovasc. Pharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1298\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:15:28Z","timestamp":1786954528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":94,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081298"],"URL":"https:\/\/doi.org\/10.3390\/ph19081298","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}